Allogeneic hematopoietic cell transplantation improves outcome
of adults with t(6;9) acute myeloid leukemia: results from an
international collaborative study

J 2020

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study

KAYSER, Sabine, Robert K. HILLS, Marlise R. LUSKIN, Andrew M. BRUNNER, Christine TERRE et. al.

Základní údaje

Originální název

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study

Autoři

KAYSER, Sabine (276 Německo, garant), Robert K. HILLS (826 Velká Británie a Severní Irsko), Marlise R. LUSKIN (840 Spojené státy), Andrew M. BRUNNER (840 Spojené státy), Christine TERRE (250 Francie), Jorg WESTERMANN (276 Německo), Kamal MENGHRAJANI (840 Spojené státy), Carole SHAW (840 Spojené státy), Maria R. BAER (840 Spojené státy), Michelle A. ELLIOTT (840 Spojené státy), Alexander E. PERL (840 Spojené státy), Zdeněk RÁČIL (203 Česká republika, domácí), Jiří MAYER (203 Česká republika, domácí), Pavel ZAK (203 Česká republika), Tomas SZOTKOWSKI (203 Česká republika), Stephane DE BOTTON (250 Francie), David GRIMWADE (826 Velká Británie a Severní Irsko), Karin MAYER (276 Německo), Roland B. WALTER (840 Spojené státy), Alwin KRAMER (276 Německo), Alan K. BURNETT (826 Velká Británie a Severní Irsko), Anthony D. HO (276 Německo), Uwe PLATZBECKER (276 Německo), Christian THIEDE (276 Německo), Gerhard EHNINGER (276 Německo), Richard M. STONE (840 Spojené státy), Christoph ROLLIG (276 Německo), Martin S. TALLMAN (840 Spojené státy), Elihu H. ESTEY (840 Spojené státy), Carsten MULLER-TIDOW (276 Německo), Nigel H. RUSSELL (826 Velká Británie a Severní Irsko), Richard F. SCHLENK (276 Německo) a Mark J. LEVIS (840 Spojené státy)

Vydání

Haematologica, PAVIA, FERRATA STORTI FOUNDATION, 2020, 0390-6078

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Itálie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 9.941

Kód RIV

RIV/00216224:14110/20:00118595

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3324/haematol.2018.208678

UT WoS

000505041200031

Klíčová slova anglicky

HIGH-DOSE CYTARABINE; ACUTE MYELOGENOUS LEUKEMIA; FLT3 GENE; AML; T(6/9)(P23_Q34); INDUCTION; CONSOLIDATION; CHEMOTHERAPY; PROGNOSIS; SURVIVAL

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 17. 2. 2020 15:35, Mgr. Tereza Miškechová

Anotace

V originále

A cute myeloid leukemia (AML) with t(6;9)(p22;q34) is a distinct entity accounting for 1-2% of AML cases. A substantial proportion of these patients have a concomitant FLT3-ITD. While outcomes are dismal intensive chemotherapy, limited evidence suggests allogeneic hematopoietic cell transplantation (allo-HCT) may improve survival if performed early during first complete remission. We report on a cohort of 178 patients with t(6;9)(p22;q34) within an international, multicenter collaboration. Median age was 46 years (range: 16-76), AML was de novo in 88%, FLT3-ITD was present in 62%, and additional cytogenetic abnormalities in 21%. Complete remission was achieved in 81% (n=144), including 14 patients who received high-dose cytarabine after initial induction failure. With a median follow up of 5.43 years, estimated overall survival at five years was 38% (95%CI: 31-47%). Allo-HCT was performed in 117 (66%) patients, including 89 in first complete remission. Allo-HCT in first complete remission was associated with higher 5-year relapse-free and overall survival as compared to consolidation chemotherapy: 45% (95%CI: 35-59%) and 53% (95%CI: 42-66%) versus 7% (95%CI: 3-19%) and 23% (95%CI: 13-38%), respectively. For patients undergoing allo-HCT, there was no difference in overall survival rates at five years according to whether it was performed in first [53% (95%CI: 42-66%)], or second [58% (95%CI: 31-100%); n=10] complete remission or with active disease/relapse [54% (95%CI: 34-84%); n=18] (P=0.67). Neither FLT3-ITD nor additional chromosomal abnormalities impacted survival. In conclusion, outcomes of t(6;9)(p22;q34) AML are poor with chemotherapy, and can be substantially improved with allo-HCT.

Návaznosti

NV15-25809A, projekt VaV

Název: Národní program studia mutací a klonality leukemických buněk u pacientů s akutní myeloidní leukémií

Citovat

KAYSER, Sabine, Robert K. HILLS, Marlise R. LUSKIN, Andrew M. BRUNNER, Christine TERRE, Jorg WESTERMANN, Kamal MENGHRAJANI, Carole SHAW, Maria R. BAER, Michelle A. ELLIOTT, Alexander E. PERL, Zdeněk RÁČIL, Jiří MAYER, Pavel ZAK, Tomas SZOTKOWSKI, Stephane DE BOTTON, David GRIMWADE, Karin MAYER, Roland B. WALTER, Alwin KRAMER, Alan K. BURNETT, Anthony D. HO, Uwe PLATZBECKER, Christian THIEDE, Gerhard EHNINGER, Richard M. STONE, Christoph ROLLIG, Martin S. TALLMAN, Elihu H. ESTEY, Carsten MULLER-TIDOW, Nigel H. RUSSELL, Richard F. SCHLENK a Mark J. LEVIS. Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. Haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2020, roč. 105, č. 1, s. 161-169. ISSN 0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2018.208678.

@article{1623358,
   author = {Kayser, Sabine and Hills, Robert K. and Luskin, Marlise R. and Brunner, Andrew M. and Terre, Christine and Westermann, Jorg and Menghrajani, Kamal and Shaw, Carole and Baer, Maria R. and Elliott, Michelle A. and Perl, Alexander E. and Ráčil, Zdeněk and Mayer, Jiří and Zak, Pavel and Szotkowski, Tomas and de Botton, Stephane and Grimwade, David and Mayer, Karin and Walter, Roland B. and Kramer, Alwin and Burnett, Alan K. and Ho, Anthony D. and Platzbecker, Uwe and Thiede, Christian and Ehninger, Gerhard and Stone, Richard M. and Rollig, Christoph and Tallman, Martin S. and Estey, Elihu H. and MullerandTidow, Carsten and Russell, Nigel H. and Schlenk, Richard F. and Levis, Mark J.},
   article_location = {PAVIA},
   article_number = {1},
   doi = {http://dx.doi.org/10.3324/haematol.2018.208678},
   keywords = {HIGH-DOSE CYTARABINE; ACUTE MYELOGENOUS LEUKEMIA; FLT3 GENE; AML; T(6/9)(P23_Q34); INDUCTION; CONSOLIDATION; CHEMOTHERAPY; PROGNOSIS; SURVIVAL},
   language = {eng},
   issn = {0390-6078},
   journal = {Haematologica},
   title = {Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study},
   url = {http://dx.doi.org/10.3324/haematol.2018.208678},
   volume = {105},
   year = {2020}
}

TY  - JOUR
ID  - 1623358
AU  - Kayser, Sabine - Hills, Robert K. - Luskin, Marlise R. - Brunner, Andrew M. - Terre, Christine - Westermann, Jorg - Menghrajani, Kamal - Shaw, Carole - Baer, Maria R. - Elliott, Michelle A. - Perl, Alexander E. - Ráčil, Zdeněk - Mayer, Jiří - Zak, Pavel - Szotkowski, Tomas - de Botton, Stephane - Grimwade, David - Mayer, Karin - Walter, Roland B. - Kramer, Alwin - Burnett, Alan K. - Ho, Anthony D. - Platzbecker, Uwe - Thiede, Christian - Ehninger, Gerhard - Stone, Richard M. - Rollig, Christoph - Tallman, Martin S. - Estey, Elihu H. - Muller-Tidow, Carsten - Russell, Nigel H. - Schlenk, Richard F. - Levis, Mark J.
PY  - 2020
TI  - Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study
JF  - Haematologica
VL  - 105
IS  - 1
SP  - 161-169
EP  - 161-169
PB  - FERRATA STORTI FOUNDATION
SN  - 03906078
KW  - HIGH-DOSE CYTARABINE
KW  - ACUTE MYELOGENOUS LEUKEMIA
KW  - FLT3 GENE
KW  - AML
KW  - T(6/9)(P23_Q34)
KW  - INDUCTION
KW  - CONSOLIDATION
KW  - CHEMOTHERAPY
KW  - PROGNOSIS
KW  - SURVIVAL
UR  - http://dx.doi.org/10.3324/haematol.2018.208678
L2  - http://dx.doi.org/10.3324/haematol.2018.208678
N2  - A cute myeloid leukemia (AML) with t(6;9)(p22;q34) is a distinct entity accounting for 1-2% of AML cases. A substantial proportion of these patients have a concomitant FLT3-ITD. While outcomes are dismal intensive chemotherapy, limited evidence suggests allogeneic hematopoietic cell transplantation (allo-HCT) may improve survival if performed early during first complete remission. We report on a cohort of 178 patients with t(6;9)(p22;q34) within an international, multicenter collaboration. Median age was 46 years (range: 16-76), AML was de novo in 88%, FLT3-ITD was present in 62%, and additional cytogenetic abnormalities in 21%. Complete remission was achieved in 81% (n=144), including 14 patients who received high-dose cytarabine after initial induction failure. With a median follow up of 5.43 years, estimated overall survival at five years was 38% (95%CI: 31-47%). Allo-HCT was performed in 117 (66%) patients, including 89 in first complete remission. Allo-HCT in first complete remission was associated with higher 5-year relapse-free and overall survival as compared to consolidation chemotherapy: 45% (95%CI: 35-59%) and 53% (95%CI: 42-66%) versus 7% (95%CI: 3-19%) and 23% (95%CI: 13-38%), respectively. For patients undergoing allo-HCT, there was no difference in overall survival rates at five years according to whether it was performed in first [53% (95%CI: 42-66%)], or second [58% (95%CI: 31-100%); n=10] complete remission or with active disease/relapse [54% (95%CI: 34-84%); n=18] (P=0.67). Neither FLT3-ITD nor additional chromosomal abnormalities impacted survival. In conclusion, outcomes of t(6;9)(p22;q34) AML are poor with chemotherapy, and can be substantially improved with allo-HCT.
ER  -

KAYSER, Sabine, Robert K. HILLS, Marlise R. LUSKIN, Andrew M. BRUNNER, Christine TERRE, Jorg WESTERMANN, Kamal MENGHRAJANI, Carole SHAW, Maria R. BAER, Michelle A. ELLIOTT, Alexander E. PERL, Zdeněk RÁČIL, Jiří MAYER, Pavel ZAK, Tomas SZOTKOWSKI, Stephane DE BOTTON, David GRIMWADE, Karin MAYER, Roland B. WALTER, Alwin KRAMER, Alan K. BURNETT, Anthony D. HO, Uwe PLATZBECKER, Christian THIEDE, Gerhard EHNINGER, Richard M. STONE, Christoph ROLLIG, Martin S. TALLMAN, Elihu H. ESTEY, Carsten MULLER-TIDOW, Nigel H. RUSSELL, Richard F. SCHLENK a Mark J. LEVIS. Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. \textit{Haematologica}. PAVIA: FERRATA STORTI FOUNDATION, 2020, roč.~105, č.~1, s.~161-169. ISSN~0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2018.208678.

Podrobný výpis o publikaci